Comparative Pharmacology
Head-to-head clinical analysis: DOXERCALCIFEROL versus HECTOROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXERCALCIFEROL versus HECTOROL.
DOXERCALCIFEROL vs HECTOROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxercalciferol is a synthetic vitamin D2 analog that undergoes hepatic conversion to its active metabolite, 1α,25-dihydroxyvitamin D2, which binds to the vitamin D receptor (VDR) in the parathyroid glands, reducing parathyroid hormone (PTH) synthesis and secretion. It also increases intestinal calcium and phosphate absorption and promotes bone mineralization.
Synthetic vitamin D analog that binds to vitamin D receptors (VDR), increasing intestinal absorption of calcium and phosphate, and promoting bone mineralization. Also suppresses parathyroid hormone (PTH) production.
0.5 mcg orally three times per week at each hemodialysis session; alternatively, 1 mcg orally three times per week. Intravenous: 0.5 mcg bolus three times per week at end of hemodialysis; titrate to target intact parathyroid hormone (iPTH) level.
0.5 to 1.5 mcg intravenously three times weekly during hemodialysis; adjust to maintain serum intact PTH within target range (1.5 to 3 times upper limit of normal). Initial dose: 0.5 mcg three times weekly; may increase by 0.25 to 0.5 mcg at 2- to 4-week intervals.
None Documented
None Documented
Clinical Note
moderateDoxercalciferol + Hydrochlorothiazide
"Doxercalciferol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateDoxercalciferol + Bendroflumethiazide
"Doxercalciferol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateDoxercalciferol + Methyclothiazide
"Doxercalciferol may increase the hypercalcemic activities of Methyclothiazide."
Clinical Note
moderateDoxercalciferol + Hydroflumethiazide
Terminal elimination half-life is approximately 96 hours (range 48–168 hours) in patients with chronic kidney disease, reflecting slow release from adipose tissue and prolonged vitamin D receptor activation.
Terminal elimination half-life is approximately 5.0 hours in healthy adults; prolonged in patients with hepatic impairment.
Primarily fecal (biliary) elimination; renal excretion accounts for <2% of unchanged drug in urine.
Primarily hepatic metabolism followed by biliary excretion; renal excretion accounts for <2% of unchanged drug.
Category A/B
Category C
Vitamin D Analog
Vitamin D Analog
"Doxercalciferol may increase the hypercalcemic activities of Hydroflumethiazide."